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Abstract
Severe sepsis is increasingly a cause of death. Rapid and correct initial antimicrobial treatment reduces mortality. The aetiological
agent(s) cannot always be found in blood cultures (BCs). A novel multiplex PCR test (SeptiFast (alpha version)) that allows identiﬁcation
of 20 bacterial and fungal species directly from blood was used, comparatively with BC, in a multicentre trial of patients with suspected
bacterial or fungal sepsis. Five hundred and ﬁfty-eight paired samples from 359 patients were evaluated. The rate of positivity was 17%
for BC and 26% for SeptiFast. Ninety-six microorganisms were isolated with BC, and 186 microorganisms were identiﬁed with SeptiFast;
231 microrganisms were found by combining the two tests. Of the 96 isolates identiﬁed with BC, 22 isolates were considered to be
contaminants. Of the remaining 74 non-contaminant BC isolates available for comparison with SeptiFast, 50 were identiﬁed as a species
identical to the species identiﬁed with SeptiFast in the paired sample. Of the remaining 24 BC isolates for which the species, identiﬁed
in the BC, could not be detected in the paired SeptiFast sample, 18 BC isolates were identiﬁed as a species included in the SeptiFast
master list, and six BC isolates were identiﬁed as a species not included in the SeptiFast master list. With SeptiFast, 186 microorganisms
were identiﬁed, 12 of which were considered to be contaminants. Of the 174 clinically relevant microorganisms identiﬁed with SeptiFast,
50 (29%) were detected by BC. More than half of the remaining microorganisms identiﬁed with SeptiFast (but not isolated after BC)
were also found in routine cultures of other relevant samples taken from the patients. Future clinical studies should assess whether the
use of SeptiFast is of signiﬁcant advantage in the detection of bloodstream pathogens.
Keywords: Blood culture, LightCycler, multiplex, PCR, sepsis, SeptiFast
Original Submission: 26 February 2007; Revised Submission: 18 September 2008; Accepted: 18 September 2008
Editor: D. Mack
Clin Microbiol Infect 2009; 15: 544–551
Corresponding author and reprint requests: H. Westh,
Department of Clinical Microbiology 445, Hvidovre Hospital,
Kettega˚rd Alle 30, DK-2650 Hvidovre, Denmark
E-mail: henrik.westh@hvh.regionh.dk
*These authors contributed equally to this work.
LightCycler, SeptiFast, MGRADE, MagNA Lyser and AmpErase are
trademarks of Roche Molecular Diagnostics.
Introduction
Sepsis represents a rising healthcare burden. The incidence
of sepsis is increasing, as is the number of sepsis-related
deaths [1]. There were 659 935 cases of sepsis reported in
the USA in 2000, with a bias towards men (relative risk 1.3)
and with an average mortality rate of 18%. Ten bacterial
species (fungi were not investigated) found in the SENTRY
Antimicrobial Surveillance Program (1997–2002) accounted
for 89–92% of all isolates. The ranking of the presence of
these species was very similar across North America, Latin
America, and Europe [2]. In the USA, a nationwide hospital
study of 24 179 nosocomial bloodstream infections showed
that the nine most frequent bacterial pathogens were all
included in the ten most frequent pathogens found in the
SENTRY surveillance, with Candida being the fourth most
common pathogen isolated [3].
The goal of blood culture (BC) in septic patients is to
isolate a microorganism for identiﬁcation, susceptibility test-
ing, and typing, in order to optimize initial empirical ther-
apy. Rapid and correct initial antimicrobial treatment is
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crucial for successful treatment of septic patients [4–7].
Many years of research in BC technology has led to
improved culture media and automated BC systems with
increased sensitivity, inactivation of antimicrobial agents,
rapid detection of microbial growth, and improved detec-
tion of fungi and fastidious microorganisms [8,9]. Despite
such advances, the rates of positive BC from patients with
different categories of sepsis vary greatly, depending on the
degree of sepsis [10–12].
PCR assays developed for speciﬁc detection of pathogens
in the blood were described as early as 1993 [13–16].
Further development led to broad-spectrum PCR
assays, allowing more universal detection of microorganisms
[17–20]. Such broad-spectrum PCR methodology has been
hampered by problems of contamination. Contaminating
microbial DNA can be introduced either during the sampling
process or by handling in the microbiology laboratory
[18,21–23]. In particular, PCR assay kit components, such as
reagents for DNA extraction [24] and polymerases, are usu-
ally contaminated [25,26]. In addition, reservations have been
voiced concerning the ability of PCR to achieve the required
sensitivity, because of small sample volumes and the per-
ceived necessity for an initial (and time-consuming) enrich-
ment step involving microbial growth [27]. The diversity of
the pathogens concerned necessitates the incorporation of
multiple probes for multiple targets, once again prompting
questions about the ease of use of the test and the time
required to obtain results.
SeptiFast has recently been used in the molecular diagnosis
of sepsis in neutropenic patients [28] and in emergency
room, intensive-care unit and general medicine patients with
suspected bloodstream infection [29]. We describe a large
multicentre evaluation of SeptiFast, which was designed to be
sensitive and rapid and to allow the identiﬁcation of 20 spe-
cies of bacteria and fungi that are responsible for up to 95%
of all positive BCs.
Materials and Methods
Material
This multicentre study was initiated and performed in six
centres; in each centre, 31–129 episodes were included
between June and October 2004. An episode was deﬁned as
a BC and a simultaneously obtained blood sample for the
SeptiFast test. All patients included were clinically suspected
to have bacterial or fungal sepsis. Signs of the systemic
inﬂammatory response syndrome (temperature, heart rate,
respiratory rate, and white blood cell count) were recorded
for all patients and registered in a case report form. Data
registered in the case report form also included antimicrobial
therapy and the suspected focus of infection. A patient could
be included with more than one episode (one to three epi-
sodes per patient). The results of the SeptiFast test were not
used to guide clinical treatment. The relevant institutional or
regional review boards or ethics committees approved the
research protocol, and participants gave written informed
consent, except in one centre, where this was not required
by the local ethics committee.
Methods
Blood culture, blood for the SeptiFast test and supplementary
microbiological samples. Skin disinfection was performed twice,
with ethanol (70%) or propanol (70%), and blood for the BC
was drawn by a phlebotomist wearing sterile gloves. A single
venipuncture was used to draw samples for 2 · 2 bottles of
BacT/Alert (Biomerieux S.A., Marcy-l Etoile, France) (30–
40 mL of blood) or three bottles of BACTEC (BD Diagnos-
tics, Sparks, MD, USA) (25–30 mL of blood). Immediately
after blood was drawn for BC (8–10 mL per BC bottle),
5 mL of whole blood was collected in sterile VACUETTE
EDTA K2E tubes (Greiner Bio-One, Frickenhausen, Ger-
many) for the alpha version of the SeptiFast test (see below).
Each BC was performed in a pair of aerobic/anaerobic bot-
tles. Blood for one or two additional BC sets was collected
from each patient within a 24-h period and included in epi-
sode evaluation. The BCs were analysed using the semi-auto-
mated blood culture systems BACTEC or BacT/ALERT,
according to laboratory-deﬁned standard operating proce-
dures, and time to culture positivity was registered. System-
atic collection of samples from other body sites was not part
of the protocol. Microbiological results from supplementary
samples were obtained only when clinical indications were
present. Identiﬁcation of microorganisms from a suspected
infectious focus within 48 h of the episode was used to
resolve discrepancies in the results.
The SeptiFast kit. The internal transcribed sequences located
between the bacterial 16S and 23S ribosomal RNA genes
and the fungal 18S and 5.6S ribosomal RNA genes were
selected as the targets for ampliﬁcation and microorganism
identiﬁcation (Roche Diagnostics GmbH, Penzberg,
Germany) [30,31]. Information concerning the sequences of
primers and probes is proprietary. A SeptiFast test was taken
to be positive when an internal hybridization probe emitted
a ﬂuorescent signal above a deﬁned threshold level. The spe-
cies identiﬁcation of a positive SeptiFast test was based upon
a subsequent melting curve analysis.
The analytical sensitivity of the assay as determined by the
manufacturer is between 3 and 100 CFU/mL, depending on
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the microorganism (Table 1). All reagents, instruments and
disposables were obtained from Roche Molecular Diagnostics
(Roche Diagnostics GmbH, Penzberg, Germany).
Sample preparation for the SeptiFast test and the PCR
procedure The preparation of DNA and testing were
performed as recommended by the manufacturer, using the
alpha version of the SeptiFast lys kit, the SeptiFast prep kit,
and the LightCycler SeptiFast kit, which were similar but not
identical to the commercially available products. The princi-
pal difference between the alpha version of the SeptiFast kit
and the commercial SeptiFast kit is the automated identiﬁca-
tion of species and controls by the SeptiFast identiﬁcation
software, where low concentrations of streptococci and
coagulase-negative staphylococci (CoNS) are not displayed as
positive results [30]. These ‘low copy number positives’ can
be found manually by examining the ampliﬁcation and melting
curve data obtained from the ‘Gram-positive’ capillary.
All MGRADE reagents and disposables used in the Septi-
Fast test were produced using stringent DNA-depleting
procedures as stated by the manufacturer. The mechanical
lysis of the bacteria was performed using the SeptiFast lys kit
and the MagNA Lyser instrument. After the MagNA Lyser
procedure was performed, the internal control (IC) of the
LightCycler SeptiFast kit was added to each sample and to
the negative control (NC). Manual DNA extraction was
performed according to the manufacturer’s instructions,
using the SeptiFast prep kit. Blood (in two aliquots of
1.5 mL) was lysed in the MagNA Lyser, using glass beads.
Subsequently, total DNA was extracted from 2 mL and
eluted in a ﬁnal volume of 300 lL. Fifty microlitres was used
for each LightCycler capillary. The amount of DNA available
for ampliﬁcation in each SeptiFast capillary originated from
1/3 mL of blood, as compared with the 30–40 mL of blood
obtained for a BC set.
Potential amplicon contaminations were eliminated using
AmpErase (Roche Diagnostics). The eluates were then sub-
jected to multiplex real-time PCR analysis, using the LightCy-
cler 2.0 instrument (Roche). LightCycler data were only
considered valid if the corresponding assay controls (reagent
control and the IC of the NC) were in the assigned Tm range
and the NC was negative. A complete SeptiFast workﬂow
included samples from seven patients and was analysed in 6 h.
Data analysis and interpretation A non-contaminant, positive
BC result was assumed to represent a true infection accord-
ing to previously published data [32–34]. Microorganisms
contained in the SeptiFast master list (Table 1) were identi-
ﬁed by characteristic peaks recognized with LightCycler soft-
ware and by manual analysis of Tm values. The SeptiFast test
was recorded as negative when the IC was positive and no
other signals were detected. SeptiFast samples with a nega-
tive IC (as a sign of potential inhibition) were included in the
study as negative results.
Whether microorganisms identiﬁed with the SeptiFast test
represented a true infection was evaluated retrospectively by
considering the identity of the microorganism and the focus
of infection as diagnosed by the clinician, and by comparing
the BC results with ﬁndings from other clinical specimens.
Evaluation of BC and SeptiFast test contaminants Typical BC
contaminants (CoNS, Streptococcus spp., Propionibacterium
spp., and Bacillus spp.) were identiﬁed by the local investiga-
tors. Generally, isolates were considered to be contaminants
if only one positive BC result was available within 48 h.
If two BC results were obtained with different samples from
the same patient within 48 h, including one positive and one
negative result, the positive BC was considered to be
contaminated. However, if both results within this time per-
iod were positive, they were considered to indicate infection.
In cases where three samples were drawn from the same
patient within the same 48-h period, the patient was consid-
ered to have an infection if two of the three samples or all
three samples yielded the same microorganism. The BC was
considered to be contaminated if only one of three samples
from the 48-h period was culture-positive [32–36].
TABLE 1. Multiplex PCR test SeptiFast master list; the
bacteria and fungi listed can be detected by a three-
capillary multiplex real-time LightCycler 2.0 system (limits
of detection of microorganisms are described in the
footnotesa)
Gram-negative Gram-positive Fungi
Escherichia colib Staphylococcus aureusc Candida albicansc
Klebsiella
(pneumoniaec/oxytocac)
Coagulase-negative
staphylococcid
Candida tropicalisc
Serratia marcescensb Streptococcus pneumoniaec Candida parapsilosisc
Enterobacter
(cloacaec/aerogenesc)
Streptococcus spp.e Candida glabrata
Proteus mirabilisb Enterococcus faeciumc Candida kruseic
Pseudomonas aeruginosab Enterococcus faecalisc Aspergillus fumigatusb
Acinetobacter baumanniic – –
Stenotrophomonas maltophiliac – –
aLimit of detection of microorganisms as described in the package insert of the
commercial assay: all microorganisms in the SeptiFast master list found at con-
centrations of 100 CFU/mL.
bMicroorganisms found in 20/20; analysis at 3 CFU/mL.
cMicroorganisms found in 20/20; analysis at 30 CFU/mL.
dThe coagulase-negative staphylococci that can be identiﬁed with the commer-
cial assay are described in the package insert as S. epidermidis, S. hemolyticus,
S. hominis, S. pasteuri, S. warneri, S. cohnii, S. lugdenensis, S. capitis, S. caprae, S. sap-
hrophyticus, and S. xylosis.
eThe Streptococcus species that can be identiﬁed with the commercial assay are
described in the package insert as S. agalactiae, S. pyogenes, S. anginosus, S. bovis,
S. constellatus, S. cristatus, S. gotdonii, S. intermedius, S. milleri, S. mitis, S. mutans, S.
oralis, S. parasanguinis, S. salivarius, S. sanguinis, S. thermophilus, S. vestibularis, and
S. viridans.
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Evaluation of a SeptiFast test result as contaminant was
performed for CoNS and Streptococcus spp. on the basis
of the following criteria: (i) BC bottles were negative; (ii)
time to positive BC with contaminant was more than
24 h; (iii) microorganisms were not found in other culture
specimens; and (iv) the crossing point (CP) was higher
than 35 cycles.
This CP cut-off value was calculated from an in-house
(Roche) experiment, in which a SeptiFast test was performed
with samples from healthy participants and in which low
copy numbers and high CP values were found for occasional
CoNS and less frequent streptococci (data not shown).
No other bacteria, or fungi, were found in these healthy
participants.
Statistical methods The McNemar test was used for testing
the differences between paired proportions. Comparisons
of episodes and isolates/microorganisms were made using
chi-square tests, with Yates’ correction when the number of
samples was <20.
Overall agreement between blood culture and SeptiFast Analyses
of overall agreement between the ﬁndings from the
SeptiFast test and BC were performed as follows: ﬁrst, as
an episode-to-episode comparison (Table 2)—positive
episode agreement between the two tests could be
achieved in spite of the identiﬁcation of different clinical
isolates/microorganisms with the two tests; and second, as
an isolate-to-microorganism comparison (Table 3)—this
could be considered to be a more direct comparison of
the two tests than the episode-to-episode comparison. In
the assessment of agreement, contaminant episodes or
contaminant isolates/microorganisms were included, even
though the two test systems could be contaminated at
different phases and therefore could not be expected to
ﬁnd the same contaminant [37].
Results
Patients
Three hundred and ﬁfty-nine patients were included in the
study. From these patients, 558 episodes fulﬁlled the inclu-
sion criteria of the study, with BC and SeptiFast samples
obtained simultaneously. Of these, 382 episodes were nega-
tive in both BC and SeptiFast, and 176 episodes were posi-
tive in at least one test system (Table 2). The 176 positive
episodes resulted in a total of 231 isolates/microrganisms
found by either of the two methodologies (Table 4). Seventy
episodes (12.5%) in which the IC was negative in the Septi-
Fast test were included in the study as SeptiFast negatives.
BC and SeptiFast episodes
For BC, the positive episode rate was 17% (96/558). Of the
96 positive episodes, 74 episodes contained clinical isolates
and 22 episodes contained contaminant BC isolates only.
The positive episode rate of SeptiFast was 26% (144/558). Of
the 144 SeptiFast-positive episodes, 138 contained clinical
microorganisms (six contaminants were found with clinical
microorganisms), and six episodes contained contaminants
only. The BC contamination rate was 3.9% (22/558), and the
contamination rate for SeptiFast was 2.2% (12/558). Excluding
contaminants, the positive rate of SeptiFast was twice as high
as that of BC (25%, 138/558 vs. 13%, 74/558; Table 2).
BC and SeptiFast isolates/microorganisms
In this study, a single microorganism was detected in 74
non-contaminant positive BCs. Polymicrobial infection, how-
ever, was detected by SeptiFast at an average of 1.3 microor-
ganisms per sample (112 episodes with one microorganism,
18 episodes with two microorganisms, six episodes with
three microorganisms, and two episodes with four microor-
ganisms). Fifty of the 74 positive BC isolates (68%) were
TABLE 2. Episode agreement between blood culture and
SeptiFast test
Blood culture
Positive Negative Contaminant Total
SeptiFast
Positive 58 77 3 138
Negative 16 382 16 414
Contaminant 0 3 3 6
Total 74 462 22 558
Signiﬁcantly more episodes were positive by SeptiFast (p <0.0001).
Overall percentage agreement, (58 + 382 + 3)/558: 79% (95% CI 76–83%).
Agreement of SeptiFast with positive blood culture, 58/74: 78% (95% CI
67–87%).
Agreement of SeptiFast with negative blood culture, 382/462: 83% (95% CI
79–86%).
TABLE 3. Isolate/microorganism agreement between blood
culture and SeptiFast test
Blood culture
Positive Negative Contaminant Total
SeptiFast
Positive 50 124 0 174
Negative 24 382 21 427
Contaminant 0 11 1 12
Total 74 517 22 613
Signiﬁcantly more microorganisms were identiﬁed by SeptiFast, p <0.0001.
Overall percentage agreement, (50 + 382 + 1)/613: 71% (95% CI 67–74%).
Agreement of SeptiFast with positive blood culture, 50/74: 68% (95% CI
56–78%).
Agreement of SeptiFast with negative blood culture, 382/517: 74% (95% CI
70–78%).
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detected with both systems. Of the 24 BC-positive but Septi-
Fast-negative isolates, six isolates were not included and 18
isolates (ten different species) were included in the list of
microorganisms that can be detected by SeptiFast (Table 1).
The 174 SeptiFast clinical microorganisms (Table 3) were
detected in 138 episodes. Of the 174 microorganisms, 50
(29%) microorganisms were also detected by BC. Of the 124
microorganisms detected only by SeptiFast, 67 (54%) could
be conﬁrmed as clinical pathogens by culture of the same
microorganism/species from a relevant anatomical site within
the same clinical time frame. The remaining 57 microorgan-
isms found using SeptiFast only could not be conﬁrmed, as
the microorganism did not grow in culture from a clinically
relevant site or because samples from such a site were not
obtained. In total, 117/174 (67%) microorganisms found using
SeptiFast could be conﬁrmed by culture. The isolates/micro-
organisms found using BC and/or SeptiFast are shown in
Table 4.
Episodes where Staphylococcus aureus was found by BC
and using SeptiFast had a mean CP of 26.8 (standard devia-
tion 3.8), whereas episodes that were SeptiFast-positive and
BC-negative had a mean CP of 29.7 (standard deviation 3.8).
This difference in CP suggests that the amount of S. aureus
DNA present in SeptiFast samples where the paired BC sam-
ple is negative is signiﬁcantly lower than the amount of
S. aureus DNA present in SeptiFast samples where the paired
BC sample is positive.
Low-level contamination in SeptiFast
Low-level contamination (included as a negative result) in the
SeptiFast PCR (a CP higher than 35 cycles) was seen in 57
episodes due to CoNS and in two cases due to Streptococcus
spp. (11%, in 558 episodes).
Agreement between BC and SeptiFast results
The overall episode-to-episode agreement (positives with
positives plus negatives with negatives) between SeptiFast
and BC was 79% (Table 2). For positive SeptiFast results, the
agreement with BC was 78%, and for negative SeptiFast
results, the agreement with BC was 83% (Table 2).
The overall microorganism-to-isolate agreement between
SeptiFast and BC was 71% (Table 3). For positive SeptiFast
results, the agreement with BC was 68%, and for negative
SeptiFast results, the agreement with BC was 74%
(Table 3).
In the absence of a laboratory reference standard for the
diagnosis of sepsis, we compared the two tests in three dif-
ferent ways: (i) the BC result is 100% accurate; (ii) the Septi-
Fast result is 100% accurate; and (iii) the combined ﬁndings
by BC or SeptiFast, excluding contaminant isolates/microor-
ganisms, are 100% accurate. An analysis of the positive ﬁnd-
ings consequently leads to different sensitivity rates for BC
and SeptiFast. On the basis of these deﬁnitions, the sensitivity
of BC (ability to ﬁnd a positive result) would be 29% if Septi-
Fast were used as the standard. On the other hand, the sen-
sitivity of SeptiFast would be 68% if BC were the reference
standard. If all non-contaminant ﬁndings by BC or SeptiFast
were regarded as true positives, the sensitivity of BC would
be 37%, and that of SeptiFast would be 88%.
Inﬂuence of antimicrobial therapy on BC and SeptiFast test
results
SeptiFast detected 124 microorganisms in patients for whom
the paired BC was negative. In 64 (52%, 95% CI 42–61%) of
these episodes, at the time of sampling the patient had
received antimicrobial therapy considered likely to be effec-
tive against the microorganism detected using SeptiFast. BC
detected 74 isolates. In 27 (37%, 95% CI 27–49%) of
these BC episodes, at the time of sampling the patient
had received antimicrobial therapy effective against the
microorganism.
TABLE 4. Number of microorganisms/isolates detected
with SeptiFast or blood culture
Pathogen
Any
system
Both
systems
Septi
Fast
only
Blood
culture
only pa
Gram-positive
Staphylococcus aureus 32 12 20 0 <0.0001
Streptococcus spp. 16 5 9 2 NS
Enterococcus faecalis 14 5 7 2 NS
Enterococcus faecium 14 2 8 4 NS
Staphylococcus spp. 11 8 2 1 NS
Streptococcus pneumoniae 3 0 2 1 NS
Gram-negative
Escherichia coli 27 10 16 1 <0.0001
Stenotrophomonas maltophilia 12 2 10 0 <0.002
Klebsiella pneumoniae/oxytoca 11 0 10 1 <0.01
Enterobacter cloacae/aerogenes 8 0 8 0 <0.008
Pseudomonas aeruginosa 6 0 5 1 NS
Serratia marcescens 1 1 0 0 NS
Fungi
Candida albicans 17 2 13 2 <0.008
Aspergillus fumigatus 12 0 12 0 <0.0005
Candida parapsilosis 7 2 2 3 NS
Candida tropicalis 1 1 0 0 NS
Not in SeptiFast master list 6 0 0 6 –
Subtotal 198 50 124 24 <0.0001
Contaminant microrganisms/isolates
Staphylococcus spp. 19 1 2 16 –
Streptococcus spp. 10 0 9 1 –
Propionibacterium spp.b 3 0 0 3 –
Bacillus spp.b 1 0 0 1 –
Subtotal 33 1 11 21 –
Total 231
NS, not signiﬁcant.
aThe McNemar test was used for testing the difference between paired propor-
tions (SeptiFast only vs. blood culture only).
bNot included in the SeptiFast master list.
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Time to positive BC or SeptiFast test
The time to a positive result was documented in 36 of 50
episodes during which the same microorganism was detected
using BC and SeptiFast. The median time to the ﬁrst positive
BC signal (equalling the time to Gram stain—not the time to
the ﬁnal species identiﬁcation) was 2 days (range: 1–10 days).
If SeptiFast had been performed on a once-daily basis (not as
batched runs, as in this study), the average time from obtain-
ing the sample to the SeptiFast result would be a median of
18 h (range: 6–30 h).
Discussion
The purpose (and design) of this study was to compare
SeptiFast test results with BC results—not to assess the
potential clinical value of the SeptiFast test when used in
addition to BC. This latter issue can only be examined by
controlled clinical trials evaluating the impact of SeptiFast test
results on patient care and outcome variables.
We observed more episodes of circulating bacterial and/
or fungal DNA detected using SeptiFast than episodes in
which microorganisms were detected using BC, as observed
in other studies [28,29]. In particular, we found more epi-
sodes with S. aureus, Escherichia coli, Candida albicans, Aspergil-
lus fumigatus, Stenotrophomonas maltophilia, Klebsiella
pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Ente-
robacter aerogenes. Although the numbers are small, it
appears that, for Candida spp. and A. fumigatus, the SeptiFast
methodology was more sensitive than conventional BC, sug-
gesting that some fungal infections in intensive-care unit
patients might currently be undiagnosed. The detection of
A. fumigatus DNA was unexpected, as this microorganism is
difﬁcult to detect with current conventional technology
[38,39]. In only two of ﬁve patients, A. fumigatus infection
was conﬁrmed by other diagnostic methods, autopsy and
bronchoalvelolar lavage, as the cause of endocarditis and
pneumonia, respectively. Diagnostic tests for Aspergillus were
not performed for the other three patients. Recently, two
neutropenic patients with haematological malignancies have
also been found to be A. fumigatus-positive using SeptiFast
and bronchoalvelolar lavage [28]. Speciﬁcally designed studies
will be needed to investigate the clinical signiﬁcance of posi-
tive SeptiFast results for A. fumigatus in suspected A. fumigatus
infections. Patients who were positive for S. aureus by both
BC and SeptiFast had lower CPs (more target) than did
patients for whom BC was negative and SeptiFast positive for
S. aureus. This may explain, in part, why BC was negative in
these cases. The interpretation of Streptococcus spp. and
CoNS as non-contaminant microorganisms was based on
simultaneous ﬁndings of these microorganisms using SeptiFast
and culture. This could be imprecise, as species determina-
tion cannot be performed for Streptococcus spp. and CoNS
detected with the SeptiFast test. The contamination rate was
slightly lower for SeptiFast (2.2%) than it was for BC (3.9%).
This was primarily due to the CP cut-off value of 35 cycles
deﬁned in the software for CoNS and streptococci.
The most important advantage of BC over SeptiFast is that
susceptibility testing of an isolate can be performed, allowing
the implementation of speciﬁcally targeted antimicrobial or
antifungal therapy. BC also has an advantage over SeptiFast
with respect to microorganisms not included in the SeptiFast
master list. In some cases, microorganisms were identiﬁed by
BC that theoretically should have been found using SeptiFast.
This probably happened in cases of low-level bacteraemia,
where there was no target for SeptiFast in the sample tested.
Unfortunately, IC DNA in the SeptiFast assay was not ampli-
ﬁed in 12.5% of episodes; therefore, the SeptiFast test gave
no information. This was due to either inhibition of the PCR
reaction or inappropriate sample preparation, both of which
must be addressed in future improvements of the assay [40].
Early appropriate antimicrobial treatment of sepsis
has been demonstrated in several studies to improve survival
[4–7,41]. The diagnosis of bacteraemia can be complicated in
patients receiving antimicrobial treatment, and all current BC
systems have been modiﬁed in an attempt to reduce the
effect of antimicrobials in the BC bottle [42]. The advantage
of a DNA-based detection system (as compared with BC) is
that the microorganism causing sepsis does not have to be
viable at the time of sampling. Although our data in this
respect are limited, owing to the design of the study, Septi-
Fast may be particularly advantageous for patients receiving
antibiotics.
One question that must be answered by future studies
concerns the clinical relevance of microorganisms detected
only by SeptiFast. It is not clear whether DNAaemia as
revealed by the SeptiFast test reﬂects true infection. Analysis
of BCs and other routine clinical microbiology samples
revealed that 67% of the microorganisms detected using
SeptiFast could be conﬁrmed by culture. This is in agreement
with the 69% conﬁrmation rate found in a previous study
[29]. The present study was not designed to evaluate the
clinical signiﬁcance of microbial DNAaemia, which is certainly
not the same as, and therefore not directly comparable with,
bacteraemia. We believe that further studies are needed to
address this issue.
We observed an ‘overall agreement’ between SeptiFast
and BC results of 79%. Similar imperfect overall agreements
have previously been found when clinical microbiology meth-
ods, such as culture of Chlamydia or viruses, have been
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replaced by much more sensitive nucleic acid ampliﬁcation
methods [43]. Finally, if any non-contaminant microorganisms
found using BC or SeptiFast testing were viewed as true pos-
itives in septic patients, 37% of the microorganisms were
found using BC as opposed to 88% using SeptiFast testing.
The SeptiFast technology could represent an advantageous
addition to BC technology, and seems to hold promise for
enhanced detection of bacteria and fungi in patients with sus-
pected sepsis. This new test will not replace BC, which will
still be required as a prerequisite for identiﬁcation of micro-
organisms, and in particular for susceptibility testing.
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